SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Vector illustration
Manufacturing
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”
September 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Weight loss pills available: A heap of GLP-1 pills
Manufacturing
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.
September 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
China flag on bar chart concept with increasing values, economic recovery and business improving after crisis and other catastrophe as economy and businesses reopen again
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
September 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Email envelope with warning sign on white background
Manufacturing
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to implementing significant design remediations.
September 16, 2026
 · 
2 min read
 · 
Nick Paul Taylor
financial bad statistics. Stagflation, economic slow down. Consumer Price Index. cart with money falls down. bad statistics loss of money. financial crisis or bankruptcy. Money loss. Money inflation
Drug pricing
AAM sounds alarm on ‘unsustainable, race to the bottom’ for generics and biosimilars
After years of price pressures, the trade group argues “the economics of generics have deteriorated to the point where sustainability of the industry is in peril.”
September 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Creative poster collage of two business partners having deal financial payment giving money banknote isolated on beige color background.
Manufacturing
Samsung Biologics inks $262M manufacturing deal with European pharma company
The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.
September 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Businessman leader leads a team through a crisis. on a paper boat at sea with dangerous sharks A symbol of overcoming obstacles and challenges. isometric vector illustration.
C-suite
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
September 11, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Conceptual origami paper plane pulling business finance growth chart line flying upwards on blue sky background.
Manufacturing
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion of its portfolio.
September 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis - 3d illustration
Manufacturing
Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.
September 8, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business and financial crisis vector concept with businessman levitating and trying do not fall to abyss. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration
Mergers & acquisitions
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
September 2, 2026
 · 
5 min read
 · 
Nick Paul Taylor
A closed sign hanging on the door of a business
Manufacturing
Vitruvias vanishes amid thyroid tablets recall over potential ‘superpotency’ concerns
Vitruvias Therapeutics has “ceased operations” after voluntarily recalling a batch recall of generic thyroid tablets due to possible superpotency that could cause a range of adverse events.
August 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Manufacturing
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
August 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3d rendering of Radiopharmaceuticals, these are radioactive medications or radioisotopes. These medications can be delivered orally in pill form.
Manufacturing
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.
August 25, 2026
 · 
4 min read
 · 
Nick Paul Taylor
GLP-1 weighloss pills - five pills in a row on blue background with harsh lighting - orthographic perspective
Weight loss
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
August 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Rare disease ribbon with cut-outs of people
Rare diseases
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor